Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Set the bench correctly first
Businesses across the value chain must remain agile and responsive to evolving trends to maintain competitiveness and meet changing consumer demands. For some FAB companies, increasing coverage or access to GLP-1s may offer a targeted opportunity to support workforce health and productivity - but any potential gains must be weighed against rising healthcare costs and organizational fit
Venn diagramming, GO enrichment analysis was performed using TBtools (v2.007) 53
3.2 Regeneron / Hansoh (HS-20094 GLP-1/GIP Agonist) Deal: Regeneron (U.S.) in June 2025 licensed global rights (ex-China) to HS-20094 , a dual GLP-1/GIP agonist from Chinas Hansoh Pharma
Diminished skin texture and elasticity can make you look much older than you feel
In SUSTAIN-7, a study comparing semaglutide to dulaglutide in patients with inadequately controlled T2DM, a greater reduction in body weight was observed with 0.5 mg semaglutide (4.6 kg, standard error [SE] 0.28) compared with 0.75 mg dulaglutide (2.3 kg, SE 0.27) (estimated treatment difference [ETD] 2.26 kg, 95% CI 3.02 to 1.51
US$ 20.29
US$ 24.51
US$ 23.71
US$ 22.74
